866-997-4948(US-Canada Toll Free)

Western Equine Encephalitis - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 39 Pages

Western Equine Encephalitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis Pipeline Review, H2 2016, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.

Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Western Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Western Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Western Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Western Equine Encephalitis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Western Equine Encephalitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Western Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Western Equine Encephalitis Overview 6
Therapeutics Development 7
Pipeline Products for Western Equine Encephalitis - Overview 7
Pipeline Products for Western Equine Encephalitis - Comparative Analysis 8
Western Equine Encephalitis - Therapeutics under Development by Companies 9
Western Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 10
Western Equine Encephalitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Western Equine Encephalitis - Products under Development by Companies 13
Western Equine Encephalitis - Products under Investigation by Universities/Institutes 14
Western Equine Encephalitis - Companies Involved in Therapeutics Development 15
Akshaya Bio Inc 15
Altravax Inc 16
EpiVax Inc 17
H&P Labs Inc 18
Profectus BioSciences Inc 19
Western Equine Encephalitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
DEF-201 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
equine encephalitis (trivalent) vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
equine encephalitis vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
equine encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Vaccine for Western Equine Encephalitis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Westrern Equine Encephalitis Virus Vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Western Equine Encephalitis - Dormant Projects 36
Western Equine Encephalitis - Product Development Milestones 37
Featured News & Press Releases 37
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Number of Products under Development for Western Equine Encephalitis, H2 2016 7
Number of Products under Development for Western Equine Encephalitis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Western Equine Encephalitis - Pipeline by Akshaya Bio Inc, H2 2016 15
Western Equine Encephalitis - Pipeline by Altravax Inc, H2 2016 16
Western Equine Encephalitis - Pipeline by EpiVax Inc, H2 2016 17
Western Equine Encephalitis - Pipeline by H&P Labs Inc, H2 2016 18
Western Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Western Equine Encephalitis - Dormant Projects, H2 2016 36

List of Figures
Number of Products under Development for Western Equine Encephalitis, H2 2016 7
Number of Products under Development for Western Equine Encephalitis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Top 10 Targets, H2 2016 21
Number of Products by Stage and Top 10 Targets, H2 2016 21
Number of Products by Mechanism of Actions, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *